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Abstract – Myelodysplastic syndromes (MDS) are clonal hematologic stem cell disorders with an as yet unknown molecu-
lar pathology. Genetic instability has been proposed as a cause of MDS. Mutations in the NBS1 gene, whose product nibrin 
(p95) is involved in DNA damage repair and cell-cycle control, might be associated with an elevated predisposition to the 
development of MDS. The aim of the study was to examine truncating 5 bp deletion (657del5), the most frequent NBS1 
gene mutation in Slavic populations, in MDS patients. Among 71 MDS patients, we found one case that was heterozygous 
for the NBS1 657del5 mutation. To the best of our knowledge, this is the first report of a NBS1 mutation in MDS.
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INTRODUCTION
The myelodysplastic syndrome (MDS) is character-
ized by ineffective hematopoiesis and elevated ap-
optosis in the bone marrow, resulting in peripheral 
blood cytopenias and a risk of progression to acute 
myeloid leukemia (AML).
The NBS1 gene encodes nibrin (p95), a member 
of  the  MRE11/RAD50  double-strand  break  repair 
complex (Carney et al., 1998). Protein p95 is impor-
tant for the cellular response to DNA damage (Wu et 
al., 2000), activation of cell cycle checkpoints (Zhao 
et al., 2000), processing of recombination intermedi-
ates (Tauchi et al., 2002) and telomere maintenance 
(Lombard et al., 2000).
Mutations in NBS1 are recognized as the main 
molecular event in the development of autosomal 
recessive  chromosomal  instability  disorder,  called 
Nijmegen  breakage  syndrome  (NBS).  The  clinical 
features of NBS patients are microcephaly, growth 
retardation, a “bird-like” face, radiation sensitivity, 
immunodeficiency, and increased risk of developing 
cancer, especially lymphoid malignancies. Independ-
ently from Nijmegen breakage syndrome, alterations 
in NBS1 DNA sequence are found in a number of 
malignancies. Deletion of 5 bp in exon 6 (657del5), 
resulting in a truncated protein, is the most frequent 
mutation in NBS1 in Slavic populations.
The  aim  of  the  present  study  was  to  examine 
657del5 mutation of NBS1 in a cohort of 71 MDS 
patients and to determine the potential role of this 
genetic alteration in the pathogenesis of MDS.
MATERIALS AND METHODS
This study was conducted on 71 MDS patients diag-
nosed and treated at Institute of Hematology, Clini-1056 VERA BUNJEVACKI ET AL.
cal Centre of Serbia. Among the patients, 19 were 
classified as RA, 17 as RAEB-1, 12 as RAEB-2, 15 as 
RARS and 8 remained unclassified. 
DNA was obtained from archived bone marrow 
microscope slide smears using a standard phenol-
chloroform method. 
The 657del5 mutation is a deletion of five nucle-
otides (ACAAA) that reside in exon 6 of the NBS1 
gene. To screen for 657del5, we used the polymer-
ase chain reaction (PCR) assay described by Seeman 
(Seeman et al., 2004). A fragment from NBS1 exon 6 
was amplified using the following forward and reverse 
primers: 5’-AATGTTGATC TGTCAGGACG-3’ and 
5’-TATAAATGTTTTCCCTTTGAAGA-3’ with an-
nealing temperature at 56.50C. PCR products were 
analyzed on 8% polyacrylamide gels.
Individuals  without  the  deletion  had  a  60  bp 
PCR fragment, whereas individuals heterozygous for 
deletion 657del5 displayed an additional 55 bp-long 
PCR product. 
RESULTS AND DISCUSSION
Myelodysplastic syndromes are heterogeneous and 
their primary molecular pathology is still unknown. 
A predisposition to MDS can be caused by hetero-
zygous mutations of different genes, such as GATA2 
(Hahn et al., 2011) or the genes TERC and TERT 
(Yamaguchi  et  al.,  2003),  whose  products  are  in-
volved in telomerase activity. Since genetic instabil-
ity has been discussed as a cause of MDS, mutations 
in the NBS1 gene, involved in DNA damage repair 
mechanisms and cell-cycle control, might also be as-
sociated with an elevated predisposition to the devel-
opment of MDS.
The  NBS1  gene  is  mutated  in  the  majority  of 
patients with Nijmegen breakage syndrome (NBS). 
NBS belongs to a group of autosomal recessive chro-
mosomal instability disorders, characterized by im-
munodeficiency, clonal occurrence of chromosomal 
rearrangements and hypersensitivity to irradiation. 
NBS patients have a risk of developing different ma-
lignancies, such as malignant lymphoma, acute lym-
phoblastic leukemia, glioma, medulloblastoma (van 
der Burgt et al., 1996) (Distel et al., 2003) and rhab-
domyosarcoma (der Kaloustian et al., 1996) (Meyer 
et  al.,  2004).  NBS1-heterozygous  individuals  also 
have an elevated risk of developing malignancies, in 
particular non-Hodgkin’s lymphoma, lymphoblastic 
leukemia, breast, prostate and colorectal cancers (di 
Masi, 2008).
The NBS1 gene product nibrin (p95) is a member 
of the MRE11/RAD50/p95 protein complex involved 
in DNA double-strand break repair. This complex 
is among the earliest respondents to DNA double-
strand breaks with critical roles in recognition, stabi-
lization of damage and initiation of cell-cycle check-
point signaling cascades ( Williams et al., 2007)
Due  to  impaired  DNA  repair,  NBS1-hetero-
zygous  individuals  have  higher  spontaneous  and 
induced chromosome instability. Carriers of NBS1 
mutation display a 3-fold higher rate of chromosome 
translocations compared with non-carriers (Stumm 
et al., 2001). In addition, heterozygous mutation of 
the NBS1 gene can significantly affect natural varia-
tion in gene expression (Cheung, 2006).
Experimental  support  that  NBS1  heterozygos-
ity might contribute to bone marrow failure comes 
from  studies  with  animal  models.  The  induction 
of an NBS1-null mutation in mice led to increased 
chromosome damage, radiomimetic sensitivity and 
dramatic decrease in cell survival in the bone mar-
row, thymus and spleen (Demuth et al., 2004). Ad-
ditionally, mice in which the C-terminal domain of 
nibrin was deleted showed severe apoptotic defects 
in  multiple  tissues,  including  hematopoietic  cells 
(Stracker et al., 2007).
RAD50, MRE11 and NBS1 are associated with 
the  telomeric  repeat-binding  factor,  TRF2,  during 
the S phase of cell cycle (Zhu et al., 2000), suggesting 
that p95 may have a role in telomere maintenance. 
Telomerases and the length of telomeres have an es-
sential role in the maintenance of genomic integrity 
and the long-term viability of high-renewal organ NBS1 GENE 657DEL5 MUTATION IN MDS 1057
systems. In the telomerase-defective organism, the 
proliferative capacity of hematopoietic cells in the 
bone marrow is compromised (Lee et al., 1998). The 
radiosensitivity of telomere-dysfunctional cells cor-
relates with delayed DNA break repair (Wong et al., 
2000). Mutations of TERC and TERT genes, whose 
products are the main constituents of the telomerase 
complex, are considered to cause telomere shorten-
ing, impair the proliferative capacity of hematopoiet-
ic stem cells (Vulliamy et al., 2006) and contribute to 
the development of bone marrow failure (Yamaguchi 
et al., 2005). The NBS1 gene involvement in telomere 
maintenance leads us to presume that NBS1 deficien-
cy and telomere dysfunction may act together, espe-
cially because the same correlation with the ATM 
gene has been established (Wong et al., 2003).
NBS1 has not yet been shown to be one of the 
genes  that  predispose  to  MDS;  however,  all  these 
findings encouraged us to initiate a study to find out 
whether the NBS1 gene is involved in the pathogen-
esis of this disease. We screened MDS patients for 
truncating 5-bp deletion (657del5) in exon 6 of the 
NBS1 gene because it is the most common (Varon 
et al., 1998), and carriers of this mutation are very 
frequent in populations of Slavic origin (Varon et al., 
2000). This frameshift mutation introduces a prema-
ture termination signal at codon 218 and results in a 
truncated polypeptide (Matsuura et al., 1998). Of all 
analyzed patients only one, classified as RARS MDS, 
was a carrier of the 657del mutation of the NBS1 
gene (Fig. 1). This individual was heterozygous for 
the major NBS1 mutation, 657del5 (1.41%). As far as 
we know, this is the first report of NBS1 mutation in 
MDS. Although the number of analyzed samples was 
small, our study indicates that the NBS1 gene might 
represent a potential factor involved in the pathogen-
esis of MDS. A number of questions remain open, 
especially because mutations different from 657del5 
have been identified in the NBS1 gene. Further stud-
ies are necessary to clarify the biological significance 
of the NBS1 gene in MDS.
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